Compendium of Cancer Genome Aberrations

HAEM5:B-lymphoblastic leukaemia/lymphoma with iAMP21: Difference between revisions

[checked revision][checked revision]
← Older editNewer edit →
VisualWikitext
Undo revision 14831 by Bailey.Glen (talk)
Tag: Undo
No edit summary
Line 1: Line 1:
{{DISPLAYTITLE:B-lymphoblastic leukaemia/lymphoma with iAMP21}}
{{DISPLAYTITLE:B-lymphoblastic leukaemia/lymphoma with iAMP21}}
[[HAEM5:Table_of_Contents|Haematolymphoid Tumours (5th ed.)]]
[[HAEM5:Table_of_Contents|Haematolymphoid Tumours (WHO Classification, 5th ed.)]]


<br />
<br />
Line 122: Line 122:
|X
|X
|Gain
|Gain
|EXAMPLE
|<span class="blue-text">EXAMPLE:</span>


chr7:1- 159,335,973 [hg38]
chr7:1- 159,335,973 [hg38]
|EXAMPLE
|<span class="blue-text">EXAMPLE:</span>


chr7
chr7
Line 131: Line 131:
|Yes
|Yes
|No
|No
|EXAMPLE
|<span class="blue-text">EXAMPLE:</span>


Presence of monosomy 7 (or 7q deletion) is sufficient for a diagnosis of AML with MDS-related changes when there is ≥20% blasts and no prior therapy (add reference).  Monosomy 7/7q deletion is associated with a poor prognosis in AML (add reference).
Presence of monosomy 7 (or 7q deletion) is sufficient for a diagnosis of AML with MDS-related changes when there is ≥20% blasts and no prior therapy (add reference).  Monosomy 7/7q deletion is associated with a poor prognosis in AML (add reference).
Line 137: Line 137:
|10
|10
|Gain
|Gain
|EXAMPLE
|<span class="blue-text">EXAMPLE:</span>


chr8:1-145,138,636 [hg38]
chr8:1-145,138,636 [hg38]
|EXAMPLE
|<span class="blue-text">EXAMPLE:</span>


chr8
chr8
Line 146: Line 146:
|No
|No
|No
|No
|EXAMPLE
|<span class="blue-text">EXAMPLE:</span>


Common recurrent secondary finding for t(8;21) (add reference).
Common recurrent secondary finding for t(8;21) (add reference).
Line 216: Line 216:
|-
|-
|NRAS
|NRAS
|EXAMPLE: TSG
|<span class="blue-text">EXAMPLE:</span> TSG
|45%
|45%
|EXAMPLE: IDH1 R123H
|<span class="blue-text">EXAMPLE:</span> IDH1 R123H
|EXAMPLE: EGFR amplification
|<span class="blue-text">EXAMPLE:</span> EGFR amplification
|
|
|
|
|
|
|EXAMPLE:  Excludes hairy cell leukemia (HCL) (add reference).
|<span class="blue-text">EXAMPLE:</span>  Excludes hairy cell leukemia (HCL) (add reference).
|-
|-
|KRAS
|KRAS
Line 290: Line 290:
|RUNX1
|RUNX1
|RAS pathway<ref name=":2" />
|RAS pathway<ref name=":2" />
|EXAMPLE: Increased cell growth and proliferation
|<span class="blue-text">EXAMPLE:</span> Increased cell growth and proliferation
|-
|-
|EXAMPLE: CDKN2A; Inactivating mutations
|<span class="blue-text">EXAMPLE:</span> CDKN2A; Inactivating mutations
|EXAMPLE: Cell cycle regulation
|<span class="blue-text">EXAMPLE:</span> Cell cycle regulation
|EXAMPLE: Unregulated cell division
|<span class="blue-text">EXAMPLE:</span> Unregulated cell division
|-
|-
|EXAMPLE:  KMT2C and ARID1A; Inactivating mutations
|<span class="blue-text">EXAMPLE:</span>  KMT2C and ARID1A; Inactivating mutations
|EXAMPLE:  Histone modification, chromatin remodeling
|<span class="blue-text">EXAMPLE:</span>  Histone modification, chromatin remodeling
|EXAMPLE:  Abnormal gene expression program
|<span class="blue-text">EXAMPLE:</span>  Abnormal gene expression program
|}
|}
==Genetic Diagnostic Testing Methods==
==Genetic Diagnostic Testing Methods==
Retrieved from "https://test.ccga.io/index.php/HAEM5:B-lymphoblastic_leukaemia/lymphoma_with_iAMP21"